Indexat a

Enllaç extern

Llicència i ús

Citacions

Altmetrics

Anàlisi d'autories institucional

Hernandez, A RodriguezAutor o coautor

Compartir

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Publicat a:Annals Of Oncology. 35 (9): 792-804 - 2024-09-01 35(9), DOI: 10.1016/j.annonc.2024.06.009

Autors: Arecco, L; Bruzzone, M; Bas, R; Kim, H J; Di Meglio, A; Bernstein-Molho, R; Pogoda, K; Carrasco, E; Punie, K; Bajpai, J; Agostinetto, E; Lopetegui-Lia, N; Partridge, A H; Phillips, K A; Toss, A; Rousset-Jablonski, C; Curigliano, G; Renaud, T; Ferrari, A; Paluch-Shimon, S; Fruscio, R; Cui, W; Wong, S M; Vernieri, C; Couch, F J; Dieci, M V; Matikas, A; Rozenblit, M; Mendez, D Aguilar-y; De Marchis, L; Puglisi, F; Fabi, A; Graff, S L; Witzel, I; Hernandez, A Rodriguez; Fontana, A; Pesce, R; Duchnowska, R; Pais, H L; Sini, V; Sokolovic, E; de Azambuja, E; Ceppi, M; Blondeauxt, E; Lambertini, M

Afiliacions

Resum

Background: Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its prognostic impact on prognosis of young patients harboring a pathogenic variant (PV) in the BRCA1 and/or BRCA2 genes. Patients and methods: This international, multicenter, retrospective cohort study included young patients (aged < 40 years) diagnosed with invasive breast cancer and harboring germline PVs in BRCA genes. We investigated the impact of hormone receptor status on clinical behavior and outcomes of breast cancer. Outcomes of interest [disease-free survival (DFS), breast cancer-specific fi c survival (BCSS), and overall survival (OS)] were fi rst investigated according to hormone receptor expression (positive versus negative), and then according to breast cancer subtype [luminal A-like versus luminal B-like versus triple-negative versus human epidermal growth factor receptor 2 (HER2)-positive breast cancer]. Results: From 78 centers worldwide, 4709 BRCA carriers were included, of whom 2143 (45.5%) had hormone receptor- positive and 2566 (54.5%) hormone receptor-negative breast cancer. Median follow-up was 7.9 years. The rate of distant recurrences was higher in patients with hormone receptor-positive disease (13.1% versus 9.6%, P < 0.001), while the rate of second primary breast cancer was lower (9.1% versus 14.7%, P < 0.001) compared to patients with hormone receptor-negative disease. The 8-year DFS was 65.8% and 63.4% in patients with hormone receptor-positive and negative disease, respectively. The hazard ratio of hormone receptor- positive versus negative disease changed over time for DFS, BCSS, and OS (P P < 0.05 for interaction of hormone receptor status and survival time). Patients with luminal A-like breast cancer had the worst long-term prognosis in terms of DFS compared to all the other subgroups (8-year DFS: 60.8% in luminal A-like versus 63.5% in triple- negative versus 65.5% in HER2-positive and 69.7% in luminal B-like subtype). Conclusions: In young BRCA carriers, differences in recurrence pattern and second primary breast cancer among hormone receptor-positive versus negative disease warrant consideration in counseling patients on treatment, follow-up, and risk-reducing surgery.

Paraules clau